NOTA-GZP is a high-affinity, specific granzyme B -targeted irreversible inhibitory peptide PET imaging probe. NOTA-GZP can be used for the research of colon carcinoma, melanoma [1].
In Vivo, 68Ga-NOTA-GZP (37 MBq; i.v.; single dose) PET imaging accurately reflects tumoral granzyme B expression in immunotherapy-treated colon cancer-bearing mice[1]. 68Ga-NOTA-GZP (37 MBq; i.v.; single dose) PET imaging with a mean Tmax of 1.90 in high-uptake tumors completely predicts future tumor regression in combination immunotherapy-treated colon cancer-bearing mice prior to tumor size divergence[1].
In Vitro, Non-radioactive gallium-labeled NOTA-GZP (30 min) inhibits activated human granzyme B with a Ki of 47 nM in a cell-free enzyme inhibition assay[1]. 68Ga-NOTA-GZP (30 min) exhibits 5-11 fold specificity for activated human granzyme B over other granzyme family members and pro-granzyme B in a cell-free binding assay[1].
References:
[1]. Larimer BM, et al. Granzyme B PET Imaging as a Predictive Biomarker of Immunotherapy Response. Cancer Res. 2017;77(9):2318-2327.
In Vivo, 68Ga-NOTA-GZP (37 MBq; i.v.; single dose) PET imaging accurately reflects tumoral granzyme B expression in immunotherapy-treated colon cancer-bearing mice[1]. 68Ga-NOTA-GZP (37 MBq; i.v.; single dose) PET imaging with a mean Tmax of 1.90 in high-uptake tumors completely predicts future tumor regression in combination immunotherapy-treated colon cancer-bearing mice prior to tumor size divergence[1].
In Vitro, Non-radioactive gallium-labeled NOTA-GZP (30 min) inhibits activated human granzyme B with a Ki of 47 nM in a cell-free enzyme inhibition assay[1]. 68Ga-NOTA-GZP (30 min) exhibits 5-11 fold specificity for activated human granzyme B over other granzyme family members and pro-granzyme B in a cell-free binding assay[1].
References:
[1]. Larimer BM, et al. Granzyme B PET Imaging as a Predictive Biomarker of Immunotherapy Response. Cancer Res. 2017;77(9):2318-2327.